1,027 results on '"Fujii, Hirofumi"'
Search Results
2. The 13th World Federation of Nuclear Medicine and Biology congress (WFNMB 2022): summarize the past half century and discuss the next half century of WFNMB-
3. Investigation of the Status of Unit 2 Nuclear Reactor of the Fukushima Daiichi by the Cosmic Muon Radiography
4. Investigation of Unit-1 Nuclear Reactor of the Fukushima Daiichi by Cosmic Muon Radiography
5. Dual-radionuclide in vivo imaging of micro-metastasis and lymph tract with submillimetre resolution
6. Precise characterization of a corridor-shaped structure in Khufu’s Pyramid by observation of cosmic-ray muons
7. New liposome-radionuclide-chelate combination for tumor targeting and rapid healthy tissue clearance
8. Imaging the Inner Structure of a Nuclear Reactor by Cosmic Muon Radiography
9. Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2)
10. Overview of FDG PET in Oncology in Japan
11. Cooperative recruitment of RDR6 by SGS3 and SDE5 during small interfering RNA amplification in Arabidopsis
12. Does case-mix classification affect predictions? A machine learning algorithm for surgical duration estimation
13. Simultaneous visualization of multiple radionuclides in vivo
14. Discovery of a big void in Khufu's Pyramid by observation of cosmic-ray muons
15. Protection from contamination by 211At, an enigmatic but promising alpha-particle-emitting radionuclide
16. Optimization of injection dose in 18F-FDG PET/CT based on the 2020 national diagnostic reference levels for nuclear medicine in Japan
17. αvβ3 integrin-targeted magnetic resonance imaging in a pancreatic cancer mouse model using RGD-modified liposomes encapsulated with Fe-deferoxamine.
18. CdTe XG‐Cam: A new high‐resolution x‐ray and gamma‐ray camera for studies of the pharmacokinetics of radiopharmaceuticals in small animals.
19. Nonclinical Imaging Studies for the Diagnosis of Lymph Node Metastases
20. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
21. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
22. Supplemental Table S1 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
23. Supplementary Fig. S9 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
24. Data from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
25. Equivalent prognosis with no lymph node metastasis to pathological complete remission in patients with localized advanced esophageal cancer after neoadjuvant triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative surgery: a single-center retrospective cohort study
26. Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2)
27. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis
28. The safe handling of 211At compounds
29. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
30. Recognition capability of one’s own skilled movement is dissociated from acquisition of motor skill memory
31. Novel method for screening functional antibody with comprehensive analysis of its immunoliposome
32. Radiological protection and biological COVID-19 protection in the nuclear medicine department
33. CdTe-DSD SPECT-I: An Ultrahigh-Resolution Multi-Isotope Tomographic Imager for Mice
34. MO19-3 Subgroup analyses of phase II study of weekly paclitaxel in advanced esophageal cancer that had previously received docetaxel-containing chemotherapy
35. A new simpler image quality index based on body size for FDG-PET/CT
36. Amelioration of Tumor-Promoting Microenvironment via Vascular Remodeling and CAF Suppression using E7130: Biomarker Analysis by Multi-modal Imaging Modalities
37. Overview of FDG PET in Oncology in Japan
38. Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials
39. Pyogenic granuloma originating in the pulmonary artery
40. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
41. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin
42. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial
43. 3D-OSEM versus FORE + OSEM: Optimal Reconstruction Algorithm for FDG PET with a Short Acquisition Time
44. Supplementary Figures 1 through 6 from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
45. Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table Legends from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
46. Supplementary Table 2 from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
47. Supplementary Table 1 from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
48. Supplementary Tables 3 through 6 from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
49. Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer
50. Environmental Radiation Status In and Around Tokyo Immediately After the TEPCO Fukushima Dai-ichi Nuclear Power Plant Disaster
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.